Today it was reported that the SVP & Pres, Eur, Mid-East, Afr of Boston Scientific Corp (BSX), Thepaut Eric Francis Yves, exercised options to sell 23,458 BSX shares at $8.30 a share, for a total transaction value of $879.7K.
Following Thepaut Eric Francis Yves’ last BSX Sell transaction on May 18, 2018, the stock climbed by 6.5%.
See today’s analyst top recommended stocks >>
Based on Boston Scientific Corp’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $2.39 billion and quarterly net profit of $432 million. In comparison, last year the company earned revenue of $2.22 billion and had a net profit of $283 million. BSX’s market cap is $51.1B and the company has a P/E ratio of 78.57. Currently, Boston Scientific Corp has an average volume of 3.62M.
Based on 16 analyst ratings, the analyst consensus is Strong Buy with an average price target of $42.13, reflecting a 14.9% upside. One of the top 25 analysts, according to TipRanks.com, recently recommended Buy BSX with a $40 price target.
Thepaut Eric Francis Yves’ trades have generated a -10.5% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg.
